Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic

Over a two-day-long FDA meeting, an agency panel of advisors considered dueling proposals for new renal denervation therapies—ultimately handing a thumbs-up to Otsuka’s ReCor Medical division, while delivering a narrow thumbs-down to industry giant Medtronic.